News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (ONNVF), as lead applicant with Redwood AI (RDWCF) and two Canadian research centres, has secured a Digital Health Innovation Fund grant administered by the Terry Fox Research Institute to advance SynoGraph, an AI-driven oncology platform.
The reimbursement-based award will fund up to 25% of an estimated $3.5 million project titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data.” SynoGraph will integrate federated learning and causal AI on clinico-genomic and imaging data from GSC and CRCHUQ, while Redwood AI contributes proprietary data integration and physicochemical modelling to expand its predictive core and Onco focuses on causal AI and federated pipeline development.
Onco-Innovations (OTCQB:ONNVF) announced a non-binding Letter of Intent with Ifowonco Informatics for an exclusive option and worldwide licence to Ifowonco's proprietary small-molecule inhibitor program targeting LAG-3, an immune checkpoint protein involved in T-cell regulation.
The contemplated collaboration would combine Ifowonco's oral LAG-3 inhibitors with Onco-Innovations' DNA damage response (DDR) expertise and ONC010 program to evaluate LAG-3 inhibition alone and, where supported by preclinical findings, in DDR-based combination regimens across solid tumour indications.
Onco-Innovations (OTCQB:ONNVF) reported completion of an analytical reference standard preparation program for A83B4C63, the API for its lead oncology candidate ONC010, in collaboration with Dalton Pharma Services. The work covered preparation, purification, analytical evaluation and quality assessment of highly characterized material for use in future analytical testing.
According to the company, this establishes a key analytical benchmark for future manufacturing campaigns and supports its chemistry, manufacturing and controls framework, including scale-up, regulatory readiness and progression of ONC010 toward clinical readiness within a broader analytical development strategy.
Onco-Innovations (CBOE:ONCO, OTC:ONNVF) executed a term sheet for a notional CAD$5 million non-brokered private placement of 6,764,070 Units at CAD$0.7392. Each Unit includes one Share and a three-year Warrant at CAD$0.90.
A performance-based Sharing Agreement linked to 5,159,426 Shares at CAD$0.9691 will determine net proceeds over 18 monthly tranches, with no immediate cash at closing. A CAD$400,000 corporate finance fee is payable in cash or 541,126 Units. Proceeds are intended to fund the ONC010 program, SynoGraph™ platform development, and working capital.
Onco-Innovations (OTCQB:ONNVF) has initiated polymer process development and analytical characterization work for ONC010, its lead nanoparticle-formulated PNKP inhibitor, with Nanosoft Polymers. Current activities focus on polymer synthesis optimization, characterization methods, molecular weight and polydispersity assessment, purification strategies and scalability.
This work is part of Onco’s CMC strategy and aims to build a scalable, reproducible and well-characterized polymer platform to support future GMP manufacturing, formulation work, regulatory interactions and clinical development of ONC010.
Onco-Innovations (OTCQB:ONNVF) has started three-species hepatocyte and liver microsome metabolism studies for ONC010, its lead nanoparticle-formulated PNKP inhibitor. The work, conducted by Nucro-Technics, is part of an IND-enabling strategy supporting future toxicology, pharmacokinetic modeling, dose selection and regulatory submissions.
Onco-Innovations (CBOE CA: ONCO, OTCQB: ONNVF) highlighted its role in developing next-generation DNA Damage Response (DDR) inhibitors, including ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor targeting a key DNA repair enzyme.
DDR inhibitors generated an estimated $7+ billion in 2025, with related oncology and precision medicine markets projected near $750 billion by 2030.
Onco-Innovations (OTCQB:ONNVF) signed a services agreement with Nanosoft Polymers to support development of ONC010, its lead nanoparticle-formulated PNKP inhibitor.
Nanosoft will optimize polymer process development, scale-up, analytics, formulation, and technology transfer for Onco's PEO-PBCL platform, supporting IND-enabling, GMP readiness, and future clinical studies alongside existing CMC and preclinical partners.
Onco-Innovations (OTCQB: ONNVF), a Canadian clinical-stage oncology company, is highlighted for its work on ONC010, a nanoparticle-encapsulated PNKP inhibitor targeting a DNA repair enzyme across multiple DNA repair pathways.
The company is positioned within the fast-growing DNA Damage Response inhibitor (DDRi) space, part of oncology, diagnostics and precision medicine markets projected to reach about $750 billion by 2030.
Onco-Innovations (CBOE:ONCO) plans a non-brokered private placement under the Listed Issuer Financing Exemption, offering 6,764,069 units at CAD$0.7392 for expected gross proceeds of about CAD$5 million.
Each unit includes one share and a three-year warrant exercisable at CAD$0.90, with no Canadian hold period and a minimum subscription equal to the full offering size.